# GeparNuevo (NCT02685059)

> Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02685059
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: GBG Forschungs GmbH
- Conditions: Breast Cancer
- Interventions: MEDI4736 (Anti PD-L1); Placebo; nab-Paclitaxel; Epirubicin; Cyclophosphamide
- Enrollment: 174
- Primary outcome: pathological complete response (pCR= ypT0 ypN0)

## Commentary we found

- X threads: 10
- YouTube: 9
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=geparnuevo-nct02685059

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02685059", "email": "<work email>"}; the inbox owner confirms by the emailed link.